We respond to SMC approval of ribociclib with fulvestrant for use on NHS in Scotland

The Scottish Medicines Consortium (SMC) has today (11 November 2019) announced its decision to approve ribociclib in combination with hormone therapy...

11 November 2019

We respond to ‘simple blood test for early detection of breast cancer’

A new blood test that could detect the early stages of breast cancer is being developed by scientists at the University of Nottingham. The...

4 November 2019

Breast Cancer Now responds to major new report on NHS cancer screening

Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, the research and care charity, said: "It’s extremely promising that these...

16 October 2019

Our response to draft NICE rejection of atezolizumab with nab-paclitaxel

The National Institute for Health and Care Excellence (NICE) has today (3 October 2019) announced its decision to provisionally reject immunotherapy...

3 October 2019

We respond to study suggesting being overweight as an adult lowers chance of surviving a cancer diagnosis

The study followed 47,000 women in Sweden between the ages of 29 and 49 over 20 years, with 1,500 of them developing breast or bowel cancer. The...

2 August 2019

We respond to study showing that blocking “don’t eat me” signal allows the immune system to destroy cancer cells

8 February 2019 New research from Stanford University has found that high levels of CD24 found on the surface of cancer cells can stop immune...

2 August 2019

We respond to review of the Scottish breast screening programme

31 July 2019 The Scottish Government has announced that a review of the Scottish Breast Screening Programme is to be carried out....

31 July 2019

We respond to NICE approval of ribociclib with fulvestrant for use on the Cancer Drugs Fund

17 July 2019 The National Institute for Health and Care Excellence (NICE) has today (17 July 2019) announced its decision to approve ribociclib...

19 July 2019

We respond to NICE approval of ribociclib with fulvestrant for use on the Cancer Drugs Fund

The National Institute for Health and Care Excellence (NICE) has today (17 July 2019) announced its decision to approve ribociclib in combination...

18 July 2019